Paasa Logo
Krystal Biotech, Inc. logo
KRYSNASDAQMarket closedOpens 9:30am ET

Krystal Biotech, Inc.

$335.06Last updated
-$2.02 (0.60%)Past day
Timezone

Krystal Biotech, Inc. (NASDAQ: KRYS) is trading at $335.06, about ₹32,186 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, down 0.60% today. Indian residents can buy Krystal Biotech from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$337.90
Previous close:$337.08
Volume:225.79K

Today's low

$331.78

Today's high

$338.48

52 week low

$175.85

52 week high

$382.54

KRYS opened at $337.90, closed previously at $337.08, and has traded between $175.85 and $382.54 over the past 52 weeks.

About

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Country
US
CEO
Krish S. Krishnan
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
295
Sector
Healthcare
IPO date
20/09/2017

Key statistics

Avg. volume

365.29K

Market cap

$9.88B

P/E Ratio

40.52

Price-to-sales ratio

22.42

Enterprise value

$6.65B

Free cash flow yield

2.65%

Debt-to-equity ratio

0.01

Return on equity

16.80%

ROIC

13.09%

Beta

0.54

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$389.13M

Earnings per share

$7.08

Free cash flow

$188.91M

Net profit margin

54.82%

Gross margin

93.34%

EBITDA

$196.02M

Revenue growth

33.94%

Similar securities

This is not an investment recommendation

How to buy Krystal Biotech from India

Indian residents can buy Krystal Biotech shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Krystal Biotech and place an order

    Find Krystal Biotech by name or by its ticker, KRYS, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Krystal Biotech trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Krystal Biotech position in USD and INR. Krystal Biotech pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Krystal Biotech from India

Trading and taxes when buying Krystal Biotech from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneKrystal Biotech does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Krystal Biotech stock?

Yes. Krystal Biotech (KRYS) has been listed on NASDAQ since 2017, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Krystal Biotech share cost in rupees?

One Krystal Biotech share is $335.06 — about ₹32,186 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Krystal Biotech price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Krystal Biotech from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy Krystal Biotech with less than the price of one share?

Yes. A whole Krystal Biotech share is $335.06, but there is no minimum trade size: you enter a rupee or dollar amount and receive the matching fraction.

How are gains on Krystal Biotech shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Krystal Biotech price. Paasa issues a capital-gains statement for your return.

Does Krystal Biotech pay a dividend?

No. Krystal Biotech does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Krystal Biotech from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Krystal Biotech shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Krystal Biotech shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Krystal Biotech holding, its cost and its closing value.

How do I sell Krystal Biotech and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.